Secondary Schizophrenia (64 page)

Verbaten M. N.,
et al.
Modulating
performance and subjective

cerebral blood flow in volunteers
sensory gating in healthy

experience in healthy volunteers.

with schizophrenia.

volunteers: the effects of ketamine
J Psychopharmacol, 1996.

Neuropsychopharmacology, 2005.

and haloperidol. Biol Psychiatry,
10
(2):134–40.

30
(12):2275–82.

2002.
52
(9):887–95.

92. Ragland J. D., Gur R. C., Valdez J.,
99. Honey G. D., Honey R. A. E.,

107. Heekeren K., Neukirch A.,

et al.
Event-related fMRI of
O’Loughlin C.,
et al.
Ketamine
Daumann J.,
et al.
Prepulse

disrupts frontal and hippocampal

inhibition of the startle reflex and
Organic Syndromes of Schizophrenia – Section 3

its attentional modulation in the
117. Katz M. M., Waskow I. E., Olsson
129. Sedman G., Kenna J. C. The use of
human S-ketamine and

J. Characterizing psychological

LSD-25 as a diagnostic aid in

N,N-dimethyltryptamine (DMT)

state produced by LSD. J Abnorm

doubtful cases of schizophrenia.

models of psychosis. J

Psychol, 1968.
73
(1):1–14

Br J Psychiatry, 1965.

Psychopharmacol, 2007.

118. Stone A. L., O’Brien M. S., De la
111
(470):96–100.

21
(3):312–20.

Torre A.,
et al.
Who is becoming
130. Vardy M. M., Kay S. R. LSD

108. Abel K. M., Allin M. P. G.,

hallucinogen dependent soon

psychosis or LSD-induced

Hemsley D. R.,
et al.
Low dose
after hallucinogen use starts?

schizophrenia – a multimethod

ketamine increases prepulse

Drug Alcohol Depend, 2007.

inquiry. Arch Gen Psychiatry,

inhibition in healthy men.

87
(2–3):153–63.

1983.
40
(8):877–83.

Neuropharmacology, 2003.

119. Siegel R. K., West L. J. (1975).

131. Ungerleider J.T., Fisher D. D.,
44
(6):729–37.

Hallucinations: Behavior,

Fuller M. Dangers of LSD.

109. Duncan E. J., Madonick S. H.,
experience, and theory. New York:
Analysis of 7 months’ experience

Parwani A.,
et al.
Clinical and
John Wiley & Sons.

in a university hospital’s

sensorimotor gating effects of

120. Halpern J. H. The use of

psychiatric service. JAMA, 1966.

ketamine in normals.

hallucinogens in the treatment of
197
(6):389–92

Neuropsychopharmacology, 2001.

addiction. Addict Res, 1996.

25
(1):72–83.

132. Bowers M. B., Swigar M. E.

4
(2):177–89.

Vulnerability to psychosis

110. Umbricht D., Schmid L., Koller
121. Cohen S. Lysergic-acid

associated with hallucinogen use.

R.,
et al.
Ketamine-induced
diethylamide – side-effects and

Psychiatr Res, 1983.
9
(2):91–7.

deficits in auditory and visual

complications. J Nerv Ment Dis,

context-dependent processing in

133. Potvin S., Stip E., Roy J-Y. Toxic
1960.
130
(1):30–40.

healthy volunteers – Implications
psychoses as pharmacological

for models of cognitive deficits in
122. Cholden L. S., Kurland A., Savage
models of schizophrenia. Curr

schizophrenia. Arch Gen

C. Clinical reactions and

Psychiatr Rev, 2005.
1
:23–32.

Psychiatry, 2000.
57
(12):1139–47.

tolerance to LSD in chronic

134. Langs R. J., Barr H. L. Lysergic
schizophrenia. J Nerv Ment Dis,

111. Sauer H.,

acid diethylamide (Lsd-25) and

1955.
122
(3):211–21.

Kreitschmann-Andermahr I.,

schizophrenic reactions – a

Gaser E.,
et al.
Ketamine reduces
123. Fink M., Simeon J., Haque W.,
comparative study. J Nerv Ment

the neuromagnetic mismatch

et al.
Prolonged adverse reactions
Dis, 1968.
147
(2):163.

reaction. Schizophr Res, 2000.

to LSD in psychotic subjects. Arch
135. Hollister L. E. Clinical syndrome
41
(1):148–.

Gen Psychiatry, 1966.
15
(5):450.

from LSD-25 compared with

112. O’Brien R., Cohen S. (1984).

124. Abraham H. D., Aldridge A. M.

epinephrine. Dis Nerv Syst, 1964.

Encyclopedia of Drug Abuse. New

Adverse consequences of

25
(7):427.

York: Facts on File.

lysergic-acid diethylamide.

136. Breier A. Serotonin,

113. Aghajanian G. K., Marek G. J.

Addiction, 1993.
88
(10):1327–34.

schizophrenia and antipsychotic

Serotonin model of

125. Strassman R. J. Adverse reactions
drug-action. Schizophr Res, 1995.

schizophrenia: emerging role of

to psychedelic drugs – a review of
14
(3):187–202.

glutamate mechanisms. Brain Res

the literature. J Nerv Ment Dis,

137. Riba J., Rodriguez-Fornells A.,
Rev, 2000.
31
(2–3):302–12.

1984.
172
(10):577–95.

Barbanoj M. J. Effects of

114. Henderson L. A., Glass W. J.

126. Glass G. S., Bowers M. B. Chronic
ayahuasca on sensory and

(1998). LSD: Still with Us After All
psychosis associated with

sensorimotor gating in humans as

These Years. San Francisco:

long-term psychotomimetic drug

measured by P50 suppression and

Jossey-Bass Publishers.

abuse. Arch Gen Psychiatry, 1970.

prepulse inhibition of the startle
115. Grinspoon L., Bakalar J. B. (1998).

23
(2):97.

reflex, respectively.

Psychedelic Drugs Reconsidered.

127. Abraham H. D., Aldridge A. M.,
Psychopharmacology, 2002.

New York: The Lindesmith

Gogia P. The psychopharmaco-

165
(1):18–28.

Center.

logy of hallucinogens. Neuro-

138. Umbricht D., Koller R.,

116. Houston J. (1969). Phenomenopsychopharmacology, 1996.

Vollenweider F. X.,
et al.

logy of the psychedelic

14
(4):285–98.

Mismatch negativity predicts

experience. In Psychedelic Drugs,
128. Hays P., Tilley J. R. Differences
psychotic experiences induced by

Hicks R. E. and Fink P. J. (Eds.).

between LSD psychosis and

NMDA receptor antagonist in

New York: Grune & Stratton,

schizophrenia. Can Psychiatr

healthy volunteers. Biol

pp. 1–7.

Assoc J, 1973.
18
(4):331–3.

Psychiatry, 2002.
51
(5):400–6.

Chapter 10 – Psychotomimetic effects of PCP, LSD, and Ecstasy

139. Umbricht D., Vollenweider F. X.,
NMDA antagonist

155. Cole J. C., Sumnall H. R. Altered
Schmid L.,
et al.
Effects of the
responsiveness. Neurosci Biobehav
states: the clinical effects of

5-HT2A agonist psilocybin on

Rev, 2002.
26
(4):441–55.

ecstasy. Pharmacol Therapeutics,

mismatch negativity generation

147. Noda Y., Kamei H., Mamiya T.,
2003.
98
(1):35–58.

and AX-continuous performance

et al.
Repeated phencyclidine
156. Green A. R., Mechan A. O., Elliott
task: implications for the

treatment induces negative

J. M.,
et al.
The pharmacology and
neuropharmacology of cognitive

symptom-like behavior in forced

clinical pharmacology of 3,4-

deficits in schizophrenia.

swimming test in mice: imbalance

methylenedioxymethamphetamine

Neuropsychopharmacology, 2003.

of prefrontal serotonergic and

(MDMA, “ecstasy”). Pharmacol

28
(1):170–81.

dopaminergic functions.

Rev, 2003.
55
:463–508.

140. Gouzoulis-Mayfrank E., Heekeren
Neuropsychopharmacology, 2000.

157. Landry M. J. MDMA: a review of
K., Neukirch A.,
et al.
Inhibition
23
(4):375–87.

epidemiologic data. J Psychoactive
of return in the human 5HT(2A)

148. Martin P., Carlsson M. L., Hjorth
Drugs, 2002.
34
(2):163–9.

agonist and NMDA antagonist

S. Systemic PCP treatment

model of psychosis.

158. Australian Institute of Health and
elevates brain extracellular 5-HT:
Neuropsychopharmacology, 2006.

Welfare. (2005). 2004 National

a microdialysis study in awake

31
(2):431–41.

Drug Strategy Household Survey:

rats. Neuroreport, 1998.

Detailed Findings. AIHW cat. no.

141. Halpern J. H., Pope H. G.

9
(13):2985–8.

PHE 66. Canberra: AIHW.

Hallucinogen persisting

149. Nichols C. D., Sanders-Bush E. A
perception disorder: what do we

single dose of lysergic acid

159. Australian Institute of Health and
know after 50 years? Drug Alcohol
diethylamide influences gene

Welfare. (2002). 2001 National

Depend, 2003.
69
(2):109–19.

expression patterns within the

Drug Strategy Household Survey;

First Results. AIHW cat. no. PHE

142. AbiDargham A., Laruelle M.,

mammalian brain.

35. Canberra: AIHW.

Charney D.,
et al.
Serotonin and
Neuropsychopharmacology, 2002.

schizophrenia: a review. Drugs

26
(5):634–42.

160. Degenhardt L., Copeland J.,

Today, 1996.
32
(2):171–85.

150. Solowij N. Ecstasy (3,4-

Dillon P. Recent trends in the use
of “club drugs”: an Australian

143. Iqbal N., van Praag H. M. The role
methylenedioxymethamphetamine).

review. Subst Use Misuse, 2005.

of serotonin in schizophrenia. Eur
Curr Opin Psychiatry, 1993.

40
(9–10):1241–56.

Neuropsychopharmacol., 1995.

6
:411–15.

5
:11–23.

151. Gamma A., Buck A., Berthold T.,
161. Lenton S., Boys A., Norcross K.

Raves, drugs and experience: drug
144. Amargos-Bosch M., Lopez-Gil X.,
et al.
3,4-methylenedioxymeth-use by a sample of people who
Artigas F.,
et al.
Clozapine and
amphetamine (MDMA)

attend raves in Western Australia.

olanzapine, but not haloperidol,

modulates cortical and limbic

Addiction, 1997.
92
(10):1327–37.

suppress serotonin efflux in the

brain activity as measured by

medial prefrontal cortex elicited
[(H2O)-O-15]-PET in healthy

162. Riley S. C. E., James C., Gregory
by phencyclidine and ketamine.

humans. Neuropsychophar-

D.,
et al.
Patterns of recreational
Intl J Neuropsychopharmacol,

macology, 2000.
23
(4):
drug use at dance events in

2006.
9
(5):565–73.

388–95.

Edinburgh, Scotland. Addiction,

2001.
96
(7):1035–47.

145. Lopez-Gil X., Babot Z.,

152. Parrott A. C. Human

Amargos-Bosch M.,
et al.

psychopharmacology of Ecstasy

163. Schifano F. A bitter pill. Overview
Clozapine and haloperidol

(MDMA): a review of 15 years of

of ecstasy (MDMA, MDA) related

differently suppress the

empirical research. Hum

fatalities. Psychopharmacology,